FDA grants Fast Track to Sobi's pacritinib for VEXAS syndrome

Sobi's North American subsidiary announced FDA Fast Track designation for pacritinib in VEXAS syndrome, a rare autoinflammatory disease. This accelerates regulatory review but does not guarantee approval. The designation signals unmet medical need and may boost Sobi's pipeline value.